95 related articles for article (PubMed ID: 8950473)
1. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover.
French LE; Tschopp J
Behring Inst Mitt; 1996 Oct; (97):156-60. PubMed ID: 8950473
[TBL] [Abstract][Full Text] [Related]
2. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover.
French LE; Hahne M; Viard I; Radlgruber G; Zanone R; Becker K; Müller C; Tschopp J
J Cell Biol; 1996 Apr; 133(2):335-43. PubMed ID: 8609166
[TBL] [Abstract][Full Text] [Related]
3. Fas ligand expression is restricted to nonlymphoid thymic components in situ.
French LE; Wilson A; Hahne M; Viard I; Tschopp J; MacDonald HR
J Immunol; 1997 Sep; 159(5):2196-202. PubMed ID: 9278307
[TBL] [Abstract][Full Text] [Related]
4. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
5. The role of apoptosis in normal ontogenesis and solid human neoplasms.
Kaiser HE; Bodey B
In Vivo; 2000; 14(6):789-803. PubMed ID: 11204498
[TBL] [Abstract][Full Text] [Related]
6. Expression of the Fas ligand in cells of T cell lineage.
Suda T; Okazaki T; Naito Y; Yokota T; Arai N; Ozaki S; Nakao K; Nagata S
J Immunol; 1995 Apr; 154(8):3806-13. PubMed ID: 7706720
[TBL] [Abstract][Full Text] [Related]
7. Regulation of CD95 ligand expression: a key element in immune regulation?
Brunner T; Yoo NJ; Griffith TS; Ferguson TA; Green DR
Behring Inst Mitt; 1996 Oct; (97):161-74. PubMed ID: 8950474
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma.
Choi C; Park JY; Lee J; Lim JH; Shin EC; Ahn YS; Kim CH; Kim SJ; Kim JD; Choi IS; Choi IH
J Immunol; 1999 Feb; 162(4):1889-95. PubMed ID: 9973455
[TBL] [Abstract][Full Text] [Related]
9. Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression.
Abu-Helu RF; Dimitriou ID; Kapsogeorgou EK; Moutsopoulos HM; Manoussakis MN
J Autoimmun; 2001 Sep; 17(2):141-53. PubMed ID: 11591123
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
[TBL] [Abstract][Full Text] [Related]
11. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
12. Detection of Fas and its ligand, FasL, in mouse thymus by in situ hybridization.
Gienau M; Hartmann KU
Thymus; 1997; 24(4):279-86. PubMed ID: 9493289
[TBL] [Abstract][Full Text] [Related]
13. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of the aryl hydrocarbon receptor in T-lineage cells induces thymus involution independently of the Fas/Fas ligand signaling pathway.
Nagai H; Kubo M; Abe R; Yamamoto M; Nohara K
Int Immunopharmacol; 2006 Feb; 6(2):279-86. PubMed ID: 16399633
[TBL] [Abstract][Full Text] [Related]
15. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
17. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
[TBL] [Abstract][Full Text] [Related]
18. Increased lymphocyte apoptosis in Fas ligand transgenic mice.
Cheng J; Liu C; Yang P; Zhou T; Mountz JD
J Immunol; 1997 Jul; 159(2):674-84. PubMed ID: 9218582
[TBL] [Abstract][Full Text] [Related]
19. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
20. Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells.
An S; Yap D; Knox KA
Cell Immunol; 1997 Nov; 181(2):139-52. PubMed ID: 9398401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
